Chronic liver disease constitutes a global health issue owning to their widespread prevalence and the scarcity of effective curative treatments. They are arising from various causes, both infectious and non-infectious diseases. A rapidly evolving field of interest is the use of nanoparticle (NP) systems for the safe administration of different medications and nucleic acid for the treatment of chronic liver disorder. The review examines the pathophysiology, diagnosis and new developments in nanoparticulate systems for the treatment of liver fibrosis related chronic liver disorder. Hepatic stellate cell (HSC) activation is thought to be the primary cause of liver fibrosis. Because of their unique abilities to transfer medications and other therapeutics moieties, liposomes, nanoparticulate systems have all been extensively researched. Currently, nanoparticle technology is used for liver fibrosis. Liver fibrosis can be caused by alcoholism, hepatitis viruses, genetic disorders, steatohepatitis, autoimmune, and other non-infectious conditions including fatty liver. Advanced liver fibrosis, or cirrhosis, is defined by the formation of nodules of regenerated hepatocytes after a fibrous scar caused by the accumulation of extracellular matrix (ECM) proteins disrupts the architecture of the liver. Keywords: Liver fibrosis,Nanomedicine,Therapy,Theranostics,Application